Non-peptide
Amlexanox
Also known as
Aphthasol · CHX 3673 · TBK1 IKKε inhibitor · amlexanox oral
Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.
What it is
| Small-molecule drug | Discussed for metabolic health and fat loss, and in mast-cell communities for skin reactions and food tolerance. It is not a peptide. |
|---|---|
| Capsules versus mouth paste | Swallowed capsules, including different release forms, are separate from historic Aphthasol mouth-ulcer paste. Equal milligrams do not make them interchangeable. |
Notes
Amlexanox is a small-molecule drug, not a peptide. Biohackers discuss it for metabolic health and fat loss; mast-cell communities discuss skin reactions, food tolerance and inflammation. Accounts include improvement, no change and unwanted effects. Swallowed capsules and the historic canker-sore paste are different preparations.
One compound, different uses and forms. Fat-loss and mast-cell accounts concern swallowed products, including compounded capsules. Aphthasol was a paste applied to mouth ulcers. The original discussion also names immediate-release and slower-release capsules; equal milligrams do not make these forms interchangeable. Anyone have experience with amlexanox? (Personal report · Accessed 2026-09-30)
Source context — Anyone have experience with amlexanox?: OP also appears in 1ejgtnq and is one user, not two. Their '20 or 40' is uncertain, not a precise dose band. Commercial availability anecdotes are not current supply verification or purchase guidance.
What people notice
| Skin and food reactions | Some mast-cell users describe less eczema, itching or food-related skin reaction, often with other medicines. One corrected 5 mg/day account described skin improvement without weight change. |
|---|---|
| Weight and energy vary | Accounts include looser clothes, appetite reduction and more energy, but also weeks without benefit. A randomized metabolic study found no significant weight-loss difference from placebo. |
| Sedation report corrected | The 40 mg twice-daily poster withdrew their claim that amlexanox caused morning sedation after stopping made no difference. They restarted and still reported no benefit. |
Notes
Less reactive skin or better food tolerance. MCAS means mast cell activation syndrome. Posters describe less eczema, itching or food-related skin reaction, often alongside other medicines. One food-tolerance account explicitly had not tested foods that caused respiratory reactions; skin improvement does not establish respiratory protection. Amlexanox experiences? (Personal report · Accessed 2026-09-30) · I miss food—what helped you? (Personal report · Accessed 2026-09-30)
Mast-cell reports: 5 mg once daily. The skin-benefit poster explicitly corrected an earlier 20 mg statement to 5 mg/day. This is one account, not an established minimum effective amount. Amlexanox experiences? (Personal report · Accessed 2026-09-30)
Skin improvement was still reported at two months. The low-dose skin account described continuing benefit without a weight effect. This is repeated-use history, not single-dose duration. Amlexanox experiences? (Personal report · Accessed 2026-09-30)
A leaner midsection. The existing metabolic discussion includes looser clothes after several weeks, warmer training and unchanged results. Appearance alone does not establish fat loss. The inflammation-responder pitch circulating in recaps is a hypothesis, not a reliable way to predict an individual's result.
Low appetite is possible, but not universal. An insulin-pump user mentions decreased hunger. The commercial guide repeats appetite-change claims. These reports do not make amlexanox reliably appetite-neutral or establish equivalence to a GLP-1. I miss food—what helped you? (Personal report · Accessed 2026-09-30) · Amino Asylum Amlexanox Full Review and Guide in 2025! (Community discussion · Accessed 2026-09-30)
Two weeks to 3–5 weeks are other checkpoints. One mast-cell user reported improvement after two weeks; older metabolic logs describe looser clothes at 3–5 weeks. Other people noticed nothing after weeks. What's your experience with Amlexanox? (Personal report · Accessed 2026-09-30)
Inflammation is the metabolic pitch. The research rationale involves blocking TBK1 and IKKε, enzymes involved in inflammation and energy handling. Dramatic mouse weight-loss findings helped create interest; the later randomized human study found no significant weight-loss difference from placebo. That matters when interpreting cutting claims. Inhibition of IKKε and TBK1 improves glucose control in a subset of patients with type 2 diabetes (Official context · Accessed 2026-09-30)
The sedation story was later corrected. The 40 mg twice-daily poster initially blamed morning sedation on amlexanox, then withdrew that attribution when stopping did not change it. They restarted and still noticed no benefit, with progesterone and LDN also in the picture. The reversal matters as much as the first complaint. Update on Amlexanox (Personal report · Accessed 2026-09-30)
Source context — Amlexanox experiences?: Multiple anonymous accounts, many other medicines; no confirmed diagnosis, exposure, fat loss or safety. Edited 5 mg is retained; high label maximum is not an observed dose and is not reproduced. Replies by Inevitable_Guava8906 and under_the_sunz overlap other threads, not extra independent users. Later off-medication/hospital context was found in search but not inspected in this body and is not claimed.
Source context — I miss food—what helped you?: One combined-treatment account, not a controlled interaction study. Dose not reported. Food benefit concerns skin reactions; poster explicitly had not tested foods causing respiratory reactions. No inference of respiratory protection.
Source context — Amino Asylum Amlexanox Full Review and Guide in 2025!: Product link and discount code make this commercial promotion. One claimed personal GI experience, no verified outcome series; benefit and general tolerability claims are not adopted as facts.
Source context — What's your experience with Amlexanox?: Self-reports, co-use and products incompletely specified. Same-author follow-ups are one account each. Visible body relative dates conflict with some previous frozen date annotations; precise comment dates are not newly inferred. Dose increase is reported history, not a proposed regimen.
Source context — Inhibition of IKKε and TBK1 improves glucose control in a subset of patients with type 2 diabetes: Six-person pilot and 42 randomized adults with diabetes/NAFLD, not a healthy cutting trial. Drug-specific serum levels after treatment are not an elimination half-life study. No claim of universal response. Public web tool hit recaptcha/internal error; direct HTTPS HTML fetch succeeded and selected full-body paragraphs were inspected.
Source context — Update on Amlexanox: Sedation attribution explicitly withdrawn. Progesterone and LDN co-use. New comment's '2x' wording is ambiguous and no mg amount or half-life measurement is given. The same September account is cross-posted on r/Sjogrens; not independent corroboration. Its frequency requirement is not adopted.
Doses people talk about
| Commercial chart | 10, 20 and 25+ mg/day are a promotional guide's categories. Its author reported gut distress at 25+ mg; the chart does not establish suitable amounts. |
|---|---|
| Low-dose skin account | 5 mg orally once daily. The author explicitly corrected an earlier 20 mg statement; it is one account, not an established effective minimum. |
| Other oral reports | 20 mg twice daily, 40 mg twice daily and 40 mg three times daily appear in separate accounts: 40, 80 and 120 mg/day total. |
| Different formal-study amounts | The pilot used 25 mg three times daily for two weeks, then 50 mg three times daily for ten more. The separate randomized study used 50 mg three times daily for 12 weeks in adults with diabetes and fatty liver. |
Notes
Commercial biohacking chart: 10, 20 and 25+ mg/day. A Reddit guide uses beginner, intermediate and advanced labels and includes a discount link. Its author reports gastrointestinal distress at 25+ mg and did not go higher. Those labels do not establish appropriate amounts. Amino Asylum Amlexanox Full Review and Guide in 2025! (Community discussion · Accessed 2026-09-30)
Mast-cell reports: 5 mg once daily. The skin-benefit poster explicitly corrected an earlier 20 mg statement to 5 mg/day. This is one account, not an established minimum effective amount. Amlexanox experiences? (Personal report · Accessed 2026-09-30)
Other oral accounts: 20 mg twice daily; 40 mg twice or three times daily. These total 40, 80 or 120 mg/day respectively. Benefit and nonresponse appear in separate reports. They are not evidence to escalate. What's your experience with Amlexanox? (Personal report · Accessed 2026-09-30) · Update on Amlexanox (Personal report · Accessed 2026-09-30) · Anyone have experience with amlexanox? (Personal report · Accessed 2026-09-30)
Metabolic-study tablets: 12 weeks of treatment. The six-person pilot used 25 mg three times daily for two weeks, then 50 mg three times daily for ten more: 75 then 150 mg/day. The separate randomized study used 50 mg three times daily for 12 weeks. These are research regimens in adults with diabetes and fatty liver, not community starting amounts. Inhibition of IKKε and TBK1 improves glucose control in a subset of patients with type 2 diabetes (Official context · Accessed 2026-09-30)
Source context — Amino Asylum Amlexanox Full Review and Guide in 2025!: Product link and discount code make this commercial promotion. One claimed personal GI experience, no verified outcome series; benefit and general tolerability claims are not adopted as facts.
Source context — Amlexanox experiences?: Multiple anonymous accounts, many other medicines; no confirmed diagnosis, exposure, fat loss or safety. Edited 5 mg is retained; high label maximum is not an observed dose and is not reproduced. Replies by Inevitable_Guava8906 and under_the_sunz overlap other threads, not extra independent users. Later off-medication/hospital context was found in search but not inspected in this body and is not claimed.
Source context — What's your experience with Amlexanox?: Self-reports, co-use and products incompletely specified. Same-author follow-ups are one account each. Visible body relative dates conflict with some previous frozen date annotations; precise comment dates are not newly inferred. Dose increase is reported history, not a proposed regimen.
Source context — Update on Amlexanox: Sedation attribution explicitly withdrawn. Progesterone and LDN co-use. New comment's '2x' wording is ambiguous and no mg amount or half-life measurement is given. The same September account is cross-posted on r/Sjogrens; not independent corroboration. Its frequency requirement is not adopted.
Source context — Anyone have experience with amlexanox?: OP also appears in 1ejgtnq and is one user, not two. Their '20 or 40' is uncertain, not a precise dose band. Commercial availability anecdotes are not current supply verification or purchase guidance.
Source context — Inhibition of IKKε and TBK1 improves glucose control in a subset of patients with type 2 diabetes: Six-person pilot and 42 randomized adults with diabetes/NAFLD, not a healthy cutting trial. Drug-specific serum levels after treatment are not an elimination half-life study. No claim of universal response. Public web tool hit recaptcha/internal error; direct HTTPS HTML fetch succeeded and selected full-body paragraphs were inspected.
Half-life, onset & duration
| Felt onset | One skin account improved in a week; another user reported benefit after two weeks. Metabolic logs use 3–5-week checkpoints. |
|---|---|
| Felt duration | No reliable single-dose window. Continuing skin improvement at two months describes repeated use, not the hours covered by one capsule. |
| Half-life | Capsule half-life is not established in these accounts. The measured 3.5 hours came from 100 mg of 5% mouth paste containing 5 mg active drug, not compounded capsules. |
| Blood peak — mouth paste | 2.4 hours in that mouth-paste study. It is neither capsule timing nor felt onset. |
Notes
One-week skin improvement is one account. The 5 mg poster described eczema clearing in one week. That does not establish a dependable onset clock. Amlexanox experiences? (Personal report · Accessed 2026-09-30)
Two weeks to 3–5 weeks are other checkpoints. One mast-cell user reported improvement after two weeks; older metabolic logs describe looser clothes at 3–5 weeks. Other people noticed nothing after weeks. What's your experience with Amlexanox? (Personal report · Accessed 2026-09-30)
No reliable single-dose window is reported. The day-five poster lost 4 lb in three days, which they thought was water. Later, floatiness resolved after a dose increase and weight loss stopped. That history does not measure drug clearance or hours of coverage. What's your experience with Amlexanox? (Personal report · Accessed 2026-09-30)
Skin improvement was still reported at two months. The low-dose skin account described continuing benefit without a weight effect. This is repeated-use history, not single-dose duration. Amlexanox experiences? (Personal report · Accessed 2026-09-30)
Community capsule half-life remains uncertain. A September commenter calls it short and claims three daily doses are needed for steady levels. They provide no measurement or numeric estimate. Frequency alone cannot establish how quickly the amount in the body falls by half; paste-study numbers belong to that formulation. Update on Amlexanox (Personal report · Accessed 2026-09-30)
3.5-hour half-life and 2.4-hour blood peak: mouth-paste study. The 1997 abstract reports these after 100 mg of 5% paste, containing 5 mg active amlexanox. They are formal measurements for that preparation, not a verified half-life for compounded capsules or a felt onset time. 5% amlexanox oral paste: II. Pharmacokinetics and demonstration of clinical safety (Official context · Accessed 2026-09-30)
Source context — Amlexanox experiences?: Multiple anonymous accounts, many other medicines; no confirmed diagnosis, exposure, fat loss or safety. Edited 5 mg is retained; high label maximum is not an observed dose and is not reproduced. Replies by Inevitable_Guava8906 and under_the_sunz overlap other threads, not extra independent users. Later off-medication/hospital context was found in search but not inspected in this body and is not claimed.
Source context — What's your experience with Amlexanox?: Self-reports, co-use and products incompletely specified. Same-author follow-ups are one account each. Visible body relative dates conflict with some previous frozen date annotations; precise comment dates are not newly inferred. Dose increase is reported history, not a proposed regimen.
Source context — Update on Amlexanox: Sedation attribution explicitly withdrawn. Progesterone and LDN co-use. New comment's '2x' wording is ambiguous and no mg amount or half-life measurement is given. The same September account is cross-posted on r/Sjogrens; not independent corroboration. Its frequency requirement is not adopted.
Source context — 5% amlexanox oral paste: II. Pharmacokinetics and demonstration of clinical safety: Abstract only, not full paper. This is mouth-paste administration and 5 mg active ingredient, not a measurement in compounded capsules. No safety assurance is extracted. PubMed body was empty in web tool; Europe PMC core API fetch succeeded.
Cycles people discuss
| Metabolic blocks | 4–8 and 8–12 weeks circulate, followed by reassessing laboratory results. These are informal blocks, without a validated repeat or washout schedule. |
|---|---|
| Stopping experiences differ | One month-long nonresponder noticed no worsening after stopping; another user reported a flare after interruption. The latter does not establish withdrawal rather than returning illness. |
Notes
4–8 and 8–12 weeks are circulated metabolic blocks. The existing discussion mentions reassessing glucose, insulin, A1c, liver markers and lipids rather than an indefinite cut. These blocks are not validated cycles, and resemblance to a study's length does not establish a repeat schedule or washout.
A month-long null user noticed no worsening after stopping. That individual outcome does not establish that a break is safe for others. Anyone have experience with amlexanox? (Personal report · Accessed 2026-09-30)
Another user described a flare after interruption. The account cannot distinguish withdrawal from returning illness. Amlexanox experiences? (Personal report · Accessed 2026-09-30)
Source context — Anyone have experience with amlexanox?: OP also appears in 1ejgtnq and is one user, not two. Their '20 or 40' is uncertain, not a precise dose band. Commercial availability anecdotes are not current supply verification or purchase guidance.
Source context — Amlexanox experiences?: Multiple anonymous accounts, many other medicines; no confirmed diagnosis, exposure, fat loss or safety. Edited 5 mg is retained; high label maximum is not an observed dose and is not reproduced. Replies by Inevitable_Guava8906 and under_the_sunz overlap other threads, not extra independent users. Later off-medication/hospital context was found in search but not inspected in this body and is not claimed.
Stacks
| Metabolic and inflammation talk | GLP-1 drugs, berberine, metformin and LDN appear in stack discussion. ATX-304, SLU-PP-332 and BAM15 are also named as neighboring metabolic research compounds, without a demonstrated combination benefit. |
|---|---|
| Mast-cell medicines | Reported co-use includes antihistamines and quercetin, or ketotifen. One insulin-pump user also taking a GLP-1 reported overnight low glucose after adding amlexanox. |
Notes
Stacks complicate credit and blame. The original discussion places it beside GLP-1s, berberine, metformin and occasionally LDN, plus metabolic research names ATX-304, SLU-PP-332 and BAM15. Mast-cell users also describe several medicines at once, making credit and blame hard to assign. Anyone have experience with amlexanox? (Personal report · Accessed 2026-09-30)
theshinysmith benefit with antihistamines/quercetin and 40 mg TID, lines 57–85; makwabear approximately one-month account of benefit, 14 lb lost, appetite change, heat/dehydration, headaches, spasms and dizziness, lines 120–171; Fair_Step_881 explicitly edited 20 to 5 mg once daily/capsule, one-week eczema change and two-month follow-up, lines 191–264, no weight effect lines 282–288; No_Driver_4213 flare after interruption, lines 304–325. Amlexanox experiences? (Personal report · Accessed 2026-09-30)
bikezone213 July 9 comment and same-author replies: ketotifen plus amlexanox helped regain foods; skin symptoms, decreased appetite and increased energy; insulin-pump and low-dose GLP-1 co-use with overnight low glucose. Opened body lines 233–278. I miss food—what helped you? (Personal report · Accessed 2026-09-30)
Glucose-lowering combinations need attention. One insulin-pump user also taking a GLP-1 reported lower blood glucose and overnight lows after adding amlexanox. The original notes also caution about insulin and sulfonylureas. This is a concrete co-use concern, not proof of an interaction rate. I miss food—what helped you? (Personal report · Accessed 2026-09-30)
Source context — Anyone have experience with amlexanox?: OP also appears in 1ejgtnq and is one user, not two. Their '20 or 40' is uncertain, not a precise dose band. Commercial availability anecdotes are not current supply verification or purchase guidance.
Source context — Amlexanox experiences?: Multiple anonymous accounts, many other medicines; no confirmed diagnosis, exposure, fat loss or safety. Edited 5 mg is retained; high label maximum is not an observed dose and is not reproduced. Replies by Inevitable_Guava8906 and under_the_sunz overlap other threads, not extra independent users. Later off-medication/hospital context was found in search but not inspected in this body and is not claimed.
Source context — I miss food—what helped you?: One combined-treatment account, not a controlled interaction study. Dose not reported. Food benefit concerns skin reactions; poster explicitly had not tested foods causing respiratory reactions. No inference of respiratory protection.
Watch for
| Gut, skin and activation | Reports include gut distress, constipation, anxiety, panic, racing heart and sleeplessness. Rash also occurred in supervised metabolic studies. |
|---|---|
| Benefits can include downsides | One weight-loss and energy account also described headache, dizziness, muscle spasms, drenching night sweats and dehydration. The weight change was not verified fat loss. |
| Glucose and formulation | Low glucose is a concrete concern with insulin and other glucose-lowering drugs. Mouth-paste safety history cannot establish oral-capsule safety; paste is not a swallowed-dose substitute. |
Notes
Watch for gut effects, rash and stimulation-like symptoms. Reports include gastrointestinal distress, constipation, anxiety and insomnia. Rash also occurred in supervised metabolic studies; a description of a transient study reaction does not make a new rash harmless. Amino Asylum Amlexanox Full Review and Guide in 2025! (Community discussion · Accessed 2026-09-30) · Amlexanox — starting and follow-up experiences (Personal report · Accessed 2026-09-30) · Inhibition of IKKε and TBK1 improves glucose control in a subset of patients with type 2 diabetes (Official context · Accessed 2026-09-30)
Early effects can be unwanted. One poster felt floaty on day five; another reported panic after the second 40 mg dose, and a separate first-use account described a racing heart and sleeplessness. These accounts contradict a universal promise of no stimulant-like feeling. What's your experience with Amlexanox? (Personal report · Accessed 2026-09-30) · Amlexanox — starting and follow-up experiences (Personal report · Accessed 2026-09-30)
A striking positive report can include substantial downsides. One MCAS poster described renewed exercise, more energy and 14 lb lost, but also reduced appetite, headaches, dizziness, muscle spasms and drenching night sweats with dehydration. Weight change was not verified fat loss, and the benefits and adverse experiences belong to the same person. Amlexanox experiences? (Personal report · Accessed 2026-09-30)
Glucose-lowering combinations need attention. One insulin-pump user also taking a GLP-1 reported lower blood glucose and overnight lows after adding amlexanox. The original notes also caution about insulin and sulfonylureas. This is a concrete co-use concern, not proof of an interaction rate. I miss food—what helped you? (Personal report · Accessed 2026-09-30)
Paste history does not establish capsule safety. Aphthasol information names allergy, rash, pregnancy and breastfeeding precautions. It cannot certify compounded oral use or long-term cutting. Mouth paste is not a way to meet a swallowed milligram target; liver and diabetes concerns still need proper assessment. Amlexanox: MedlinePlus Drug Information (Official context · Accessed 2026-09-30)
Source context — Amino Asylum Amlexanox Full Review and Guide in 2025!: Product link and discount code make this commercial promotion. One claimed personal GI experience, no verified outcome series; benefit and general tolerability claims are not adopted as facts.
Source context — Amlexanox — starting and follow-up experiences: Unverified compounded-product reports from people with MCAS; no causality established. Comment-specific dates April 16 and May 31 appeared in indexed search bodies, while opened page shows relative dates. The panic follow-up and first complaint belong to one person.
Source context — Inhibition of IKKε and TBK1 improves glucose control in a subset of patients with type 2 diabetes: Six-person pilot and 42 randomized adults with diabetes/NAFLD, not a healthy cutting trial. Drug-specific serum levels after treatment are not an elimination half-life study. No claim of universal response. Public web tool hit recaptcha/internal error; direct HTTPS HTML fetch succeeded and selected full-body paragraphs were inspected.
Source context — What's your experience with Amlexanox?: Self-reports, co-use and products incompletely specified. Same-author follow-ups are one account each. Visible body relative dates conflict with some previous frozen date annotations; precise comment dates are not newly inferred. Dose increase is reported history, not a proposed regimen.
Source context — Amlexanox experiences?: Multiple anonymous accounts, many other medicines; no confirmed diagnosis, exposure, fat loss or safety. Edited 5 mg is retained; high label maximum is not an observed dose and is not reproduced. Replies by Inevitable_Guava8906 and under_the_sunz overlap other threads, not extra independent users. Later off-medication/hospital context was found in search but not inspected in this body and is not claimed.
Source context — I miss food—what helped you?: One combined-treatment account, not a controlled interaction study. Dose not reported. Food benefit concerns skin reactions; poster explicitly had not tested foods causing respiratory reactions. No inference of respiratory protection.
Source context — Amlexanox: MedlinePlus Drug Information: Historic Aphthasol paste information; its US availability notice is not a current survey of compounding. Paste directions, safety history and duration are not imported into the oral-capsule practical sections.
Full notes
Amlexanox is a small-molecule drug, not a peptide. Biohackers discuss it for metabolic health and fat loss; mast-cell communities discuss skin reactions, food tolerance and inflammation. Accounts include improvement, no change and unwanted effects. Swallowed capsules and the historic canker-sore paste are different preparations.
What amlexanox is
- One compound, different uses and forms. Fat-loss and mast-cell accounts concern swallowed products, including compounded capsules. Aphthasol was a paste applied to mouth ulcers. The original discussion also names immediate-release and slower-release capsules; equal milligrams do not make these forms interchangeable. Community Personal report
- Inflammation is the metabolic pitch. The research rationale involves blocking TBK1 and IKKε, enzymes involved in inflammation and energy handling. Dramatic mouse weight-loss findings helped create interest; the later randomized human study found no significant weight-loss difference from placebo. That matters when interpreting cutting claims. Official context
What people hope to notice
- Less reactive skin or better food tolerance. MCAS means mast cell activation syndrome. Posters describe less eczema, itching or food-related skin reaction, often alongside other medicines. One food-tolerance account explicitly had not tested foods that caused respiratory reactions; skin improvement does not establish respiratory protection. Personal report Personal report
- A leaner midsection. The existing metabolic discussion includes looser clothes after several weeks, warmer training and unchanged results. Appearance alone does not establish fat loss. The inflammation-responder pitch circulating in recaps is a hypothesis, not a reliable way to predict an individual's result. Community
Doses people discuss
These are separate oral reports, not a dose ladder. Amounts below distinguish each administration from the day's total.
- Commercial biohacking chart: 10, 20 and 25+ mg/day. A Reddit guide uses beginner, intermediate and advanced labels and includes a discount link. Its author reports gastrointestinal distress at 25+ mg and did not go higher. Those labels do not establish appropriate amounts. Reddit / r/BiohackingU
- Mast-cell reports: 5 mg once daily. The skin-benefit poster explicitly corrected an earlier 20 mg statement to 5 mg/day. This is one account, not an established minimum effective amount. Personal report
- Other oral accounts: 20 mg twice daily; 40 mg twice or three times daily. These total 40, 80 or 120 mg/day respectively. Benefit and nonresponse appear in separate reports. They are not evidence to escalate. Personal report Personal report Personal report
- 40 mg once daily and meal-time splitting also circulate. The existing clinician-walkthrough discussion mentions once-, twice- and three-times-daily frequency and meals for nausea. This is attributed discussion, not a checked capsule label or a recommendation to change frequency. Community
Half-life
- Community capsule half-life remains uncertain. A September commenter calls it short and claims three daily doses are needed for steady levels. They provide no measurement or numeric estimate. Frequency alone cannot establish how quickly the amount in the body falls by half; paste-study numbers belong to that formulation. Personal report
When people notice a change
- Early effects can be unwanted. One poster felt floaty on day five; another reported panic after the second 40 mg dose, and a separate first-use account described a racing heart and sleeplessness. These accounts contradict a universal promise of no stimulant-like feeling. Personal report Personal report
- One-week skin improvement is one account. The 5 mg poster described eczema clearing in one week. That does not establish a dependable onset clock. Personal report
- Two weeks to 3–5 weeks are other checkpoints. One mast-cell user reported improvement after two weeks; older metabolic logs describe looser clothes at 3–5 weeks. Other people noticed nothing after weeks. Personal report Community
How long effects last
- No reliable single-dose window is reported. The day-five poster lost 4 lb in three days, which they thought was water. Later, floatiness resolved after a dose increase and weight loss stopped. That history does not measure drug clearance or hours of coverage. Personal report
- Skin improvement was still reported at two months. The low-dose skin account described continuing benefit without a weight effect. This is repeated-use history, not single-dose duration. Personal report
Courses and breaks people discuss
- 4–8 and 8–12 weeks are circulated metabolic blocks. The existing discussion mentions reassessing glucose, insulin, A1c, liver markers and lipids rather than an indefinite cut. These blocks are not validated cycles, and resemblance to a study's length does not establish a repeat schedule or washout. Community
- A month-long null user noticed no worsening after stopping. That individual outcome does not establish that a break is safe for others. Personal report
- Another user described a flare after interruption. The account cannot distinguish withdrawal from returning illness. Personal report
Good to know
- Watch for gut effects, rash and stimulation-like symptoms. Reports include gastrointestinal distress, constipation, anxiety and insomnia. Rash also occurred in supervised metabolic studies; a description of a transient study reaction does not make a new rash harmless. Reddit / r/BiohackingU Personal report Official context
- Glucose-lowering combinations need attention. One insulin-pump user also taking a GLP-1 reported lower blood glucose and overnight lows after adding amlexanox. The original notes also caution about insulin and sulfonylureas. This is a concrete co-use concern, not proof of an interaction rate. Personal report Community
- Paste history does not establish capsule safety. Aphthasol information names allergy, rash, pregnancy and breastfeeding precautions. It cannot certify compounded oral use or long-term cutting. Mouth paste is not a way to meet a swallowed milligram target; liver and diabetes concerns still need proper assessment. Official context Community
From community experience
- A striking positive report can include substantial downsides. One MCAS poster described renewed exercise, more energy and 14 lb lost, but also reduced appetite, headaches, dizziness, muscle spasms and drenching night sweats with dehydration. Weight change was not verified fat loss, and the benefits and adverse experiences belong to the same person. Personal report
- The sedation story was later corrected. The 40 mg twice-daily poster initially blamed morning sedation on amlexanox, then withdrew that attribution when stopping did not change it. They restarted and still noticed no benefit, with progesterone and LDN also in the picture. The reversal matters as much as the first complaint. Personal report
- Low appetite is possible, but not universal. An insulin-pump user mentions decreased hunger. The commercial guide repeats appetite-change claims. These reports do not make amlexanox reliably appetite-neutral or establish equivalence to a GLP-1. Personal report Reddit / r/BiohackingU
- Diet changes and missed doses complicate a metabolic log. An undated ResearchSafe poster describes lower glucose and weight, little appetite change, and forgetting midday doses. Diet changed too. Without inspectable tracker records, the account cannot isolate drug effects; the author's energy descriptions also differ between replies. Personal report
- Stacks complicate credit and blame. The original discussion places it beside GLP-1s, berberine, metformin and occasionally LDN, plus metabolic research names ATX-304, SLU-PP-332 and BAM15. Mast-cell users also describe several medicines at once, making credit and blame hard to assign. Community Personal report
The formal numbers behind the discussion
- Metabolic-study tablets: 12 weeks of treatment. The six-person pilot used 25 mg three times daily for two weeks, then 50 mg three times daily for ten more: 75 then 150 mg/day. The separate randomized study used 50 mg three times daily for 12 weeks. These are research regimens in adults with diabetes and fatty liver, not community starting amounts. Official context
- 3.5-hour half-life and 2.4-hour blood peak: mouth-paste study. The 1997 abstract reports these after 100 mg of 5% paste, containing 5 mg active amlexanox. They are formal measurements for that preparation, not a verified half-life for compounded capsules or a felt onset time. Official context